Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Ascend Biopharmaceuticals Ltd.
South Melbourne, Victoria, Australiaascendbiopharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Positive results from Phase 2 study of SP-002 (formerly ASN-002) in combination with vismodegib in multi-lesional Basal Cell Carcinoma patients announced in January 2025. The study demonstrated safety and efficacy of their gene therapy for patients with multiple nodular and superficial BCCs, with identification of histopathologic criteria for patient selection.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Cancer immunotherapyGene therapyAdenovirus vector (Ad-IFNγ)
- Industry
- Biotech
02
Partnerships
Stamford Pharmaceuticals (appears to be developing SP-002, formerly ASN-002)
Beyond the preview
Go deeper on Ascend Biopharmaceuticals Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ascend Biopharmaceuticals Ltd..